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Development of Allele-Specific Therapeutic
siRNA for Keratin 5 Mutations in Epidermolysis
Bullosa Simplex
Sarah D. Atkinson1,2, Victoria E. McGilligan1,2, Haihui Liao1, Ildiko Szeverenyi3, Frances J.D. Smith1,
C.B. Tara Moore1,2 and W.H. Irwin McLean1
Epidermolysis bullosa simplex (EBS) is an incurable, inherited skin-blistering disorder predominantly caused by
dominant-negative mutations in the genes encoding keratins K5 or K14. RNA interference, particularly in the
form of small interfering RNA (siRNA), offers a potential therapy route for EBS and related keratin disorders by
selectively silencing the mutant allele. Here, using a systemic screening system based on a luciferase reporter
gene assay, we have developed mutant-specific siRNAs for two independent EBS-causing missense mutations in
the K5 gene (p.Ser181Pro and p.Asn193Lys). The specificity of the allele-specific inhibitors identified in the
screen was subsequently confirmed at the protein level, where the lead inhibitors were shown to strongly
knock down the expression of mutant proteins with negligible effect on wild-type K5 expression. In a cell-based
model system, the lead inhibitors were able to significantly reverse the cytoskeletal aggregation phenotype.
Overall, this approach shows promise for the treatment of EBS and paves the way for future clinical trials.
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INTRODUCTION
Epidermolysis bullosa simplex (EBS) is an autosomal dom-
inantly inherited genodermatosis, which is characterized by
skin blistering due to fragility of the basal keratinocytes within
the epidermis (Fine et al., 2008). The mildest form of EBS is
Weber–Cockayne (OMIM #131800), where blistering is
restricted to the hands and feet; this can be a seasonal form
of EBS with increased severity during the summer months.
The recent reclassification of EB suggested the term ‘‘EBS-
localized’’ for this milder form of EBS (Fine et al., 2008). The
most severe form of EBS is Dowling–Meara (OMIM #131760)
with clustered, herpetiform blistering over the entire body,
with greatest effect on the hands and feet, which is also
affected by significant keratoderma. In recent years, advances
in immunohistochemical and molecular genetic analysis,
with the identification of causative genes for most forms of
EB, have facilitated great improvements in the diagnosis and
classification of this group of genodermatoses (Irvine and
McLean, 1999; Fine et al., 2008).
The human genes KRT5 and KRT14 encode the K5 and
K14 proteins, respectively. Heterozygous mutations in either
K5 or K14 have been shown to be the main cause of the
major EBS subtypes (Bonifas et al., 1991; Coulombe et al.,
1991; Lane et al., 1992). The EBS causative variants are
predominantly missense mutations with a smaller number of
in-frame insertion/deletion mutations, as recorded in the
interfilament database (Szeverenyi et al., 2008). The mechan-
ism of action of these defects is that of dominant-negative
inference, due to the highly polymeric nature of these
proteins (Irvine and McLean, 1999). Keratins, the type I and
type II intermediate filament proteins, form the stress-bearing
cytoskeletal network within epithelial cells, with K5 and K14
being the major keratins expressed in the basal keratinocytes
of the epidermis (Irvine and McLean, 1999). The mutations
in keratin genes associated with EBS cause structural
abberations in the cytoskeleton. Specifically, keratin
aggregates have been demonstrated within the basal kerati-
nocytes in cases of EBS Dowling–Meara (Anton-Lamprecht
and Schnyder, 1982; Ishida-Yamamoto et al., 1991) and a
filament aggregation phenotype can be recapitulated by
transient transfection of mutant keratins in cultured cells
(Coulombe et al., 1991).
In dominant-negative disorders, gene replacement therapy
may not be efficacious in all cases as the mutant allele may
interfere with a second wild-type allele (Kaspar, 2005).
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Nevertheless, overexpression of wild-type collagen VII (9:1
wild-type:mutant ratio) has been shown to improve anchor-
ing-fibril formation and has been proposed as a means of
treating dominant dystrophic epidermolysis bullosa (Fritsch
et al., 2009). An alternative means of treating dominant
keratin mutations is by gene correction via trans-splicing,
although low correction frequency remains an issue for this
method (Wally et al., 2010). However, dominant-negative
disorders such as EBS also lend themselves to therapy based
on small interfering RNA (siRNA), as reviewed in Lane and
McLean (2008) and Leachman et al. (2008). siRNAs are
double-stranded RNA molecules, which, via the RNA
interference pathway, cause specific inhibition of target gene
expression. Remarkably, it has been recently proved possible
to design exogenous siRNAs to target point mutations
(Dykxhoorn et al., 2006; Hickerson et al., 2006). This type
of therapy strategy has recently been developed for pachyo-
nychia congenita, a rare dominant-negative keratin disorder
closely related to EBS (Hickerson et al., 2008). Following the
successful preclinical studies (Hickerson et al., 2008), an
allele-specific siRNA targeting a missense mutation in K6a
has recently led to the first-in-human clinical trial for a
genetic skin disorder, where efficacy was demonstrated
in vivo (Leachman et al., 2010).
In EBS, a humanized mouse model has shown that even a
50% reduction in expression of the mutant keratin allele can
prevent the skin-blistering phenotype in vivo (Cao et al.,
2001). Here, we have developed siRNAs that are able to
specifically and potently inhibit the expression of two
independent K5 point mutations involved in EBS, with
negligible effect on wild-type K5 expression.
RESULTS
Inhibition of K5 expression by specific siRNAs
Two K5 point mutations involved in mild and severe forms of
EBS were investigated. The EBS-Dowling–Meara mutation
p.Ser181Pro is a point mutation (c.541T4C) resulting in a
serine to proline substitution in the highly conserved helix
initiation motif within the 1A domain of K5 (Shemanko et al.,
2000). The missense mutation p.Asn193Lys (due to DNA
point mutation c.579C4G) is located in the second half of
the helix 1A domain of K5, outside of the highly conserved
region (Humphries et al., 1996; Rugg et al., 2007). This
mutation has been shown to be associated with milder, site-
restricted presentation of EBS (Humphries et al., 1996; Rugg
et al., 2007).
siRNAs are generally used in a double-stranded 19þ 2
format, consisting of 19 RNA nucleotides complementary to
the target mRNA, with overhangs of two uracils or thymidine
on each strand, which facilitates entry into the RNA-induced
silencing complex within the RNA interference pathway
(Caplen et al., 2001; Elbashir et al., 2001). Thus, to target a
point mutant, there are 19 possible positions within the
siRNA molecule where the mutant base can be positioned. A
dual-luciferase reporter assay was developed to screen all 19
possible allele-specific siRNAs for each mutation to deter-
mine which siRNA had the ability to inhibit mutant K5
expression with minimal or no discernible effect on wild-type
expression. Briefly, wild-type and mutant versions of the full-
length K5 complementary DNA were cloned into the 30
untranslated region of the firefly luciferase gene in the
psiTEST-luc-target vector. These were co-transfected into
AD293 cells with a trace amount of a Renilla luciferase
expression plasmid (as a transfection efficiency and cell
viability normalization control), as well as each individual
test siRNA. The siRNA sequence walks for both K5 mutations
are shown in Supplementary Figure S1 online. siRNAs were
named as per the following example: K5-S181P-1 for the
siRNA at position 1 directed against mutation p.Ser181Pro. In
each walk, two control siRNAs were also employed—a
nonspecific negative control (NSC4; an inverted bacterial
lacZ sequence) and a positive control directed against the
luciferase gene itself (siLUC). In each experiment, siRNA
concentration was varied from 6.25 nM in 5-fold increments
down to 10 pM, so that potency could be measured, in
addition to specificity.
The full sequence walk for p.Ser181Pro is shown in
Supplementary Figure S2 online, with the most discriminating
inhibitors shown in more detail in Figure 1. Five inhibitors, at
positions 5, 6, 8, 11, and 12, showed a strong inhibitory effect
on mutant K5 expression with minimal effect on wild-type
K5 expression (Figure 1). For K5-S181P-8, -11, and -12,
there was a strong reduction in mutant allele expression even
at the lowest siRNA concentration of 10 pM. The highest
concentration of 6.25 nM resulted in an 80% reduction in
mutant expression for K5-S181P-8 and -12. The siRNAs at
positions 5 and 6 also weakly inhibited the p.Ser181Pro
mutant. The siLUC positive control inhibited the luciferase
activity of both wild-type and mutant K5 reporter genes over
a wide range of concentrations, whereas the nonspecific
control (NSC4) had no effect on either reporter gene, as
expected (Figure 1).
Similarly, all possible allele-specific siRNAs for K5
mutation p.Asn193Lys (N193K) were generated (Supplemen-
tary Figure S1 online) and used for a sequence walk against
wild-type and N193K mutant reporter gene constructs
(Supplementary Figure S2 online). Of these, siRNAs K5-
N193K-6, -7, -8, -12, and -18 reduced mutant K5 reporter
gene activity, with little effect on wild type (Figure 1). In this
instance, K5-N193K-7 and -8 were the most potent and
specific, resulting in inhibition of mutant K5 by 70–80% at the
highest siRNA concentration of 6.25 nM, with minimal effect
on wild-type reporter gene expression (Figure 1).
Western blot validation of allele-specific siRNAs
A western blot assay was utilized to further validate the
allele-specific siRNAs, which were defined from the lucifer-
ase sequence walk. These siRNAs were co-transfected at a
concentration of 5 nM with either wild-type K5 or mutant K5
into AD293 cells. A concentration of 5 nM was chosen from
preliminary optimization experiments (data not shown).
Mutant and wild-type K5–green fluorescent protein (GFP)
fusion constructs were used in transient transfection experi-
ments, plus or minus co-transfection of siRNAs under test.
Western blotting was performed using an antibody against
the GFP tag, to prevent any cross-reactivity with endogenous
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keratins expressed in AD293 cells. The lower portions of
blots were probed for K18 as an endogenous loading control.
For the p.Ser181Pro mutation, five allele-specific siRNAs
were chosen: K5-S181P-5, -6, -8, -11, and -12. These had
differing effects on the inhibition of the mutant K5/GFP
expression (Figure 2). In the western blot assay, K5-S181P-11
successfully inhibited mutant protein expression, with no
discernible effect on wild-type protein expression (Figure 2).
In contrast, K5-S181P-5, -6, and -8 had little or no effect on
both wild-type and mutant K5 expression in the western blot
assay. The final siRNA tested, K5-S181P-12, resulted in
equivalent knockdown of both wild-type and mutant K5
(Figure 2). Therefore, K5-S181P-11 was chosen as the most
specific siRNA for further testing using the filament/aggregate
phenotypic assay (below).
Figure 3 demonstrates the effect of siRNA on K5/GFP
protein expression for the p.Asn193Lys mutation. Similar to
the p.Ser181Pro mutation, five different siRNAs were chosen
from the luciferase assay: K5-N193K-6, -7, -8, -12, and -18.
Two of these, K5-N193K-8 and -12, strongly reduced
p.Asn193Lys mutant K5 protein expression with minimal
effect on wild-type K5 (Figure 3). Neither K5-N193K-6 nor -
18 had any effect on wild-type K5 but caused only very slight
inhibition of mutant K5 protein expression, i.e. these
appeared to be specific but not very potent in this assay.
Finally, K5-N193K-7 caused a reduction in expression of
mutant K5; however, it also caused a modest reduction in
wild-type K5 expression, i.e. it lacked specificity. Overall, on
the basis of its potency and specificity, K5-N193K-8 was
selected for further testing to determine its effects on keratin
filament formation.
The lead inhibitors for both mutations (K5-S181P-11 and
K5-N193K-8) were investigated for off-target effects on other
keratins in HaCat cells. Coomassie blue-stained gels showed
no reduction in any keratins expressed in this keratinocyte
cell line (Supplementary Figure S3 online). In contrast, a
positive control siRNA against K6a strongly knocked down
K6a expression at this time point (Supplementary Figure S3
online). Thus, the mutation-specific K5 siRNAs appear to be
highly specific.
Mutation-specific siRNAs significantly improve cytoskeletal
function in cultured cells
Unfortunately, appropriate patient keratinocyte cell lines
were not available corresponding to these two K5 mutations.
Therefore, epithelial cell line Ptk2 was co-transfected with
specific siRNAs and either wild-type K5/GFP or a 1:1 ratio of
both wild-type and mutant K5/GFP. The latter scenario
recapitulates the situation in EBS, where there is a 1:1 ratio
of wild-type and mutant K5 gene/protein expression. The
siRNA was used at 5 nM, as per the western blot experiments
(above). Ptk2 simple epithelial cells were used for ease of
visualization of the intermediate filaments (see Supplemen-
tary Figure S4 online) due to their flat morphology and very
limited repertoire of endogenous keratin expression (Smith
et al., 2002). For the phenotypic assay,4100 cells expressing
the GFP-tagged keratin constructs were scored at 72 hours
post-transfection for the presence of GFP-labelled filamen-
tous keratins, keratin aggregates, or a mixture of both
filamentous and aggregated keratins. This timepoint was
chosen based on preliminary time-course experiments
because at 24–48 hours post-transfection, even wild-type
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Figure 1. Inhibition of mutant K5 in AD293 cells. Each small interfering RNA (siRNA) under evaluation was co-transfected into AD293 cells, over a
concentration range (0–6.25 nM) with either a wild-type K5-luciferase reporter construct (blue line) or a mutant K5-luciferase reporter construct (red line).
Luciferase activity was measured using the dual-luciferase reporter assay 24 hours after transfection. The relative ratio of firefly luciferase was normalized to the
internal control Renilla luciferase at 0 siRNA concentration and is expressed as a percentage over the siRNA concentration range. This figure shows
the siRNAs that were used for further assessment by the western blot assay. Error bars show standard error of the mean from four replicate experiments.
Nonspecific siRNA (NSC4) had no effect; siRNA against luciferase (siLUC) inhibited both wild-type and mutant reporter constructs.
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keratins can form a high percentage of aggregates (Coulombe
et al., 1991). Examples of typical filamentous or aggregated
keratins from these experiments are shown in Supplementary
Figure S3 online. In these studies, both wild-type and mutated
keratins predominantly form aggregates at early timepoints
post-transfection; however, at later timepoints, a significantly
higher percentage of cells containing aggregates becomes
apparent in cells expressing mutant keratins. Here, we
hypothesized that the mutant-specific siRNA would be able
to reverse this effect by reducing the expression of the mutant
protein.
Figure 4a shows the data for K5 mutation p.Ser181Pro,
treated with mutation-specific K5-S181P-11. At 72 hours
post-transfection, cells transfected with only wild-type K5
and nonspecific control siRNA NSC4 predominantly formed
filamentous keratin (Figure 4a). Expression of both wild-type
and p.Ser181Pro mutant K5 plus NSC4 resulted in a
significantly higher percentage of cells containing keratin
aggregates (P¼0.001). Co-transfection of mutant-specific
K5-S181P-11 resulted in a significant reduction in cells
containing aggregates (P¼0.02) and furthermore, the per-
centage of aggregates observed was no longer signifi-
cantly different from that of cells expressing wild-type
K5 (P¼0.07).
Overall, the results for the K5 mutation p.Asn193Lys were
similar to those for the p.Ser181Pro mutation (Figure 4b);
however, the differences observed in aggregate formation
between the nonspecific siRNA-treated cells and the mutant-
targeting siRNA-treated cells were less pronounced in this
experiment. This possibly reflects the milder, site-restricted
variant of EBS caused by this particular mutation. None-
theless, expression of both wild-type and p.Asn193Lys
mutant K5 plus NSC4 resulted in a significantly higher
percentage of cells containing keratin aggregates, compared
with wild-type K5 alone plus NSC4 (P¼0.009). Co-transfec-
tion of mutant-specific K5-N193K-8 resulted in a statistically
significant reduction in cells containing aggregates
(P¼0.007) and furthermore, the percentage of aggregates
observed was no longer significantly different from that of
cells expressing wild-type K5 (P¼0.85).
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Figure 2. Confirming specificity of siRNAs at the level of protein expression.
AD293 cells were transiently co-transfected with either K5-p.Ser181Pro-GFP
or K5-GFP expression constructs and either siRNA NSC4 (a nonspecific
control) or K5-S181P-5, -6, -8, -11, or -12 at a final concentration of 5 nM.
Samples were run on a 4–12% Bis–Tris gel and transferred onto a
nitrocellulose membrane before being probed with anti-K5 and developed
with enhanced chemiluminescence. Anti-K18 was used as a loading control.
mut, mutant; wt, wild type.
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Figure 3. Cells co-transfected with a green fluorescent protein (GFP)
plasmid and mutant-specific siRNA 8 show inhibition of K5 p.Asn193Lys.
AD293 cells were transfected with 5 nM of siRNA K5-N193K-6, -7, -8, -12, or
-18 and a nonspecific control (NSC4). After 48 hours of incubation samples
were separated on a 4–12% Bis–Tris gel and transferred to a nitrocellulose
membrane before being probed with an anti-K5 antibody or K18 to
demonstrate even loading of samples. mut, mutant; wt, wild type.
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In summary, both the lead inhibitors for K5 mutations
p.Ser181Pro and p.Asn193Lys that we initially identified by
luciferase sequence walks, and whose potency and specifi-
city were subsequently confirmed by western blot, were also
able to significantly reverse the filament aggregation pheno-
type in a cell culture model of EBS.
DISCUSSION
The past two decades have seen tremendous progress in our
pathomechanistic understanding of inherited skin disease,
with the identification of hundreds of causative genes
underlying monogenic and, more recently, polygenic geno-
dermatoses. However, despite these advances, which have
greatly improved diagnosis and genetic counselling for
affected families, as well as our understanding of skin
biology, little progress has been made in translating these
discoveries into new therapies for clinical application. In the
dominantly inherited genetic disorders where the pathome-
chanism is that of dominant-negative interference, rather than
loss of function/haploinsufficiency, therapeutic approaches
such as gene replacement therapy are not appropriate, and
instead some means of silencing mutant alleles would be a
possible route to therapy (Lane and McLean, 2008; Leachman
et al., 2008). Over the years, a number of gene-silencing
methods have emerged, such as antisense RNA, morpholino
oligonucleotides, or peptide nucleic acids, which can block
translation of a target mRNA species of choice (Kaspar,
2005). Unfortunately, because they are largely based on
irreversible binding of the target mRNA by the antisense
molecule, these systems are poorly discriminating for alleles
that differ by only a few nucleotides or even a single
nucleotide. Ribozymes are catalytic RNA molecules capable
of high specificity for certain sequence contexts; however,
these are of very low efficiency and due to their large size and
dependence on correctly folded secondary structure, these
are difficult to deliver into cells (Kashani-Sabet, 2002). In
recent years, exploitation of the naturally occurring RNA
interference pathway present within all human cells, by
means of synthetic siRNA, has become the method of choice
for developing therapy based on gene silencing (Bumcrot
et al., 2006; Dykxhoorn and Lieberman, 2006). Within the
cell, siRNA enters and forms the sequence-scanning part of
the RNA-induced silencing complex—a highly processive
RNA–protein catalytic complex whose function is to select
and degrade target mRNA species. The high processivity of
RNA-induced silencing complex explains why siRNA is
highly efficacious compared with antisense methods.
In terms of physical properties, siRNA consists of a double-
stranded 19-mer RNA molecule, flanked by single-stranded
two-nucleotide overhangs. Depending on the precise nucleo-
tide sequence, siRNA typically has a molecular weight of
around 13 kDa, so that it is much closer in size to a small-
molecule drug (typically o550Da) rather than a gene
therapy vector (typically 5–10MDa). This has obvious
advantages for delivery into the skin, and currently interna-
tional efforts are ongoing in both industry and academia to
develop a non-invasive topical delivery vehicle for siRNA
(Kaspar et al., 2009).
A major challenge to the development of therapeutics
aimed at silencing mutant alleles is the requirement for a high
degree of sequence specificity. In EBS and most of the other
keratin disorders, the majority of causative mutations are
point mutations (Szeverenyi et al., 2008). Remarkably, it is
possible to develop potent, highly efficacious siRNA mole-
cules that can discriminate a single nucleotide (Yokota et al.,
2004; Dykxhoorn et al., 2006; Hickerson et al., 2006). Here,
we have adapted the recently reported fluorescent protein
sequence walk methodology (Hickerson et al., 2008) to
employ a firefly/Renilla luciferase co-reporter system. This
allows for a higher-throughput 96-well format assay, as well
as internal normalization to control for cell viability and/or
transfection efficiency. We adopted a standardized range of
siRNA concentrations from 6.25 nM down to 10 pM, so that
some measure of potency as well as sequence specificity can
be gained (Figure 1). Some of the allele-specific inhibitors
identified here are indeed highly potent, as well as show
a high degree of single-nucleotide specificity; for example,
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Figure 4. Cells transfected with siRNA have reduced aggregate formation
compared with cells transfected with a nonspecific control (NSC4). Ptk2
cells were transfected with wild-type K5/green fluorescent protein (GFP) or
mutant K5/GFP or a 1:1 ratio of both wild-type and mutated K5/GFP plasmids,
and mutant-specific siRNAs and incubated for 72 hours. The cells were fixed
and stained with 4,6-diamidino-2-phenylindole before being viewed. (a) A
graph showing the effect of siRNA K5-S181P-11 on cells transfected with both
wild-type and mutant K5 p.Ser181Pro. There was a significant difference in
aggregate formation between cells treated with siRNA 11 and those treated
with NSC4. (b) Cells treated with siRNA K5-N193K-8 had significantly less
aggregates present than cells treated with NSC4. Pp0.05 was considered
significant; black denotes the presence of filament formation, light grey the
occurrence of both filaments and aggregates, and dark grey the presence of
aggregates.
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K5-S181P–8 (Figure 1) has an IC50 of about 10 pM, which is
better than many small-molecule drugs in clinical practice.
Remarkably, the best lead inhibitors developed here are
capable of severely knocking down mutant keratin protein
expression (Figures 2 and 3), as well as reversing a readout of
cytoskeletal dysfunction in a cell culture model system
(Figure 4). The inhibitors that performed well in all three
assays are suitable for further pre-clinical development, such
as guanosine monophosphate manufacture and toxicology, to
pave the way for future clinical applications. Using methods
similar to those employed here, mutation-specific siRNA
inhibitors are in development for the K14 gene in our
laboratory.
EBS is the most common of the inherited mechanobullous
disorders, accounting for more than three quarters of the
recorded number of EB cases in some populations, despite
the likelihood that it is underreported (Horn et al., 1997;
Pfendner et al., 2001). The disorder has significant quality-of-
life issues in affected children and adults, and in the case of
the severe Dowling–Meara form of EBS the disease can be life
threatening in infants (Irvine and McLean, 1999). As one of
the first genetic skin disorders where the causative genes
were identified in the early 1990s, the pathomechanisms
underlying EBS are well understood at the levels of DNA,
RNA, and protein function. Although the disorder is
genetically heterogeneous, there are a number of recurrent
mutations that are suitable for allele-specific approaches such
as that taken here; for example, the K5 mutation p.Asn193Lys
is carried by dozens of patients in our region of the United
Kingdom (Rugg et al., 2007). Clinically, all patients with
keratin-related EBS, regardless of subtype, have areas of skin
that are particularly prone to blistering, typically on the
hands, feet, and other high-trauma body sites (Fine et al.,
2008). Overall, these features combine to make EBS an
attractive genodermatosis for development of siRNA therapy
because of the following: (a) a mutation-specific reagent
could treat several patients/families; (b) the disorder is of
sufficient burden to warrant an experimental orphan drug
type of therapy; and (c) where treatment of limited areas of
skin might significantly improve quality of life.
The biggest hurdle to clinical application of these siRNAs
is that of finding an efficacious and non-invasive delivery
system to get these small molecules across the stratum
corneum and into keratinocytes or other target cells (Kaspar,
2005; Kaspar et al., 2009). Here, we have demonstrated that
it is possible to make highly potent and mutation-specific
siRNA therapy reagents that target EBS-causing K5 mutations.
Coupled with a suitable delivery mechanism, these small
synthetic molecules have great potential for treating EBS—
currently a devastating and untreatable skin disorder.
MATERIALS AND METHODS
Design of siRNAs
In order to screen all possible sequences containing the p.Ser181Pro
and p.Asn193Lys mutations, 19 siRNAs were synthesized, each
siRNA consisted of a 19-nucleotide duplex with two 30 uracyl
nucleotide overhangs (Eurofins MWG Operon, Ebersberg,
Germany). As controls, a nonspecific siRNA and a luciferase siRNA
were also designed, acting to have no specific effect and to inhibit
the expression of luciferase, respectively. The sense sequence
of NSC4 is 50-UAGCGACUAAACACAUCAAUU-30 (inverted
b-galactosidase sequence) and the sense strand of siLUC is
50-GUGCGUUGCUAGUAC CAACUU-30 (both synthesized by
Eurofins MWG Operon).
K5-luciferase fusion constructs
Bicistronic constructs expressing both firefly luciferase and either
wild-type K5 or mutated K5 were generated by Advantagen
(Dundee, UK). Briefly, the full-length K5 complementary DNA was
cloned into a psiTEST-Luc-target reporter plasmid (York Bioscience,
York, UK).
K5-GFP constructs
A complementary DNA clone consisting of the entire open reading
frame of keratin 5 (provided by EB Lane, A*STAR Institute for
Medical Biology, Singapore) was cloned into pAcGFP-C1 (Clontech-
Takara Bio Europe, Saint-Gemain-en-Laye, France, Cat. No.
15454576) by HindIII and BamHI enzymes. Sequence variants were
generated with QuickChange Site-Directed Mutagenesis Kit (Agilent
Technologies UK, Stockport, UK, Cat. No. 200519) according to the
manufacturer’s protocol. Site-directed mutagenesis primers were
designed manually based on KRT5 sequence information (RefSeq ID,
NM_000424.3). The following primers were used to introduce the
p.Ser181Pro mutation, where the mutant bases are underlined:
c.541T4C forward (50-GACCCTCAACAATAAGTTTGCCCCCTTC
ATCGACAAGGTGCGG-30) and reverse (50-CCGCACCTTGTCGAT
GAAGGGGGCAAACTTATTGTTGAGGGTC-30). The p.Asn193Lys
mutation was introduced using the following primers: c.579C4G
forward (50-GGTTCCTGGAGCAGCAGAAGAAGGTTCTGGACAC
CAAGTGG-30) and reverse (50-CCACTTGGTGTCCAGAACCTTCT
TCTGCTGCTCCAGGAACC-30). Mutations were verified by
sequencing using ABI Big Dye terminator reaction mixture (Life
Technologies, Carlsbad, CA) according to the manufacturer’s
recommendations.
Transient transfections
Ptk2 and AD293 cells were cultured in DMEM (Invitrogen, Paisley,
UK) supplemented with 10% fetal calf serum (Invitrogen). For siRNA
screening, AD293 cells were seeded at 6.5 103 cells per well in a
96-well plate 24 hours before transfection. Cells were transfected
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. Cells were transfected in quadruplicate with
20 ng of K5-luciferase wild type or mutated, 1 ng of PRL, and the
mutation-specific siRNAs at a concentration of 0–6.25 nM; all were
diluted in OptiMEM (Invitrogen). A nonspecific control siRNA
(NSC4) and a siLUC control, which targets the luciferase component
of the vector, were also transfected at the same concentrations as the
mutation-specific siRNAs.
Luciferase reporter assay
The Dual-Luciferase Reporter Assay (Promega, Southampton, UK)
was used to measure the effect of siRNA on luciferase expression
24 hours after transfection. The assay was used according to the
manufacturer’s instructions; briefly, the medium was removed and
cells were washed with PBS before replacement with passive lysis
buffer (Promega). Cells were shaken on a plate shaker for 15minutes
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to ensure they were fully lysed, before the activities of both firefly
and Renilla luciferase were measured sequentially using the
LUMIstar OPTIMA (BMG Labtech, Aylesbury, UK).
Transient transfection of K5/GFP constructs
AD293 cells were seeded at 1 105 cells per well in a 24-well plate;
transfection was performed at the same time using Lipofectamine
2000. Cells were transfected in duplicate with 100 ng of wild-type or
mutant K5 plasmids tagged with GFP and a final concentration of
5 nM of siRNAs. The siRNAs that were transfected were either a
nonspecific control (NSC4) or mutant-specific siRNAs, which were
successful in knocking down mutated K5 as determined by the
results of the luciferase assay.
Western blot analysis
Cells were incubated for 48 hours after transfection, then washed
with PBS, and lysed with NuPAGE 1 loading and solubilization
buffer (Invitrogen). The extracted protein samples were denatured at
100 1C for 5minutes before being resolved on a 4–12% NuPAGE gel
with SDS-MOPS running buffer (Invitrogen). A SeeBlue Prestained
protein standard (Invitrogen) was also run on the gel to ensure
accurate determination of protein size. Gels were then transferred at
30V to a nitrocellulose membrane; to ensure adequate protein
transfer and equal loading of samples the membrane was stained
with Ponceau S (Sigma, Dorset, UK) before immunoblotting.
Membranes were blocked with 5% non-fat dried milk in Tris-
buffered saline for 1 hour before being probed with antibodies for
keratins 5 and 18. Expression of keratins 5 and 18 was detected by
incubating membranes for 1 hour with the following antibody
dilutions: 1:10,000 anti-K5 (rabbit polyclonal BL-18) and 1:250
anti-K18 (mouse monoclonal LDK18; a gift from EB Lane, A*STAR
Institute for Medical Biology). After primary antibody incubation the
membranes were washed in 0.05% Tween-20/Tris-buffered saline
before being incubated in a 1:1,000 dilution of either HRP-
conjugated rabbit anti-mouse or goat anti-rabbit (Dakocytomation,
Cambridgeshire, UK). Blots were again washed in 0.05%
Tween-20/Tris-buffered saline before detection using enhanced
chemiluminescence.
Transient transfection of Ptk2 cells
The siRNAs deemed most successful at targeting each mutation in
the western blotting experiment were then used to ascertain their
effect on filament and aggregate formation in vitro. Ptk2 cells were
seeded at 1 105 cells per well in a 24-well plate; each well
contained a sterile cover-slip 13mm in diameter. Transfections were
performed using Lipofectamine 2000 and cells were co-transfected
in quadruplicate with 100 ng total plasmid DNA, which was either
wild-type K5/GFP or mutant K5/GFP, or a 1:1 ratio of both wild-type
and mutated K5/GFP plasmids, and mutant-specific siRNAs (5 nM).
Cells were incubated for 72 hours with a change of media at
24 hours. After 72 hours the cells were fixed with 3% paraformalde-
hyde for 20minutes and stained with 40,6-diamidino-2-phenylindole
before being mounted onto slides with hydramount medium. At least
100 cells per coverslip were analyzed for the presence of filaments
only, aggregates only, or both filaments and aggregates. Statistical
analysis was performed on aggregate cell counts using a one-way
analysis of variance, with Po0.05 being considered significant, and
used SPSS version 17 (IBM, Somers, NY).
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